A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 7
- 试验地点
- 3
- 主要终点
- Efficacy of AEZS-108 compared to SSCC as measured by the median time of progression-free survival (PFS).
研究概览
简要总结
This is a therapeutic exploratory Phase 2 study evaluating AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival (PFS) in patients with chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
详细描述
The study will be conducted as an open-label randomized two-arm multicenter Phase II study. Patients will be randomized in a 1:1 ratio into one of the two treatment arms within each stratum: AEZS-108 (267 mg/m2 every 21 calendar days) (Arm A) OR SSCC (Arm B) at discretion of treating oncologist cycled every 21 calendar days.
Stratified randomization will be used with number of prior lines of therapies (1-2 versus >2). Tumor assessment will be repeated every 2 cycles. At the time of disease progression, Arm B patients may be crossed over to AEZS-108 as long as none of the exclusion criteria for study entry apply. Particularly, LVEF ≥50% is required, and patients failing on liposomal doxorubicin cannot be crossed over to AEZS-108.
Analysis of the main study endpoint, PFS, will follow a group sequential design with one interim and one final analysis utilizing the O'Brien-Fleming stopping boundaries procedure. The study will be terminated for futility if the lower bound is crossed and for superiority if the upper bound is crossed. The sponsor may also terminate the study for futility based on other considerations such as safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women ≥ 18 years of age
- •Histologically documented breast cancer (either primary or metastatic site) that is (i) ER-negative (0), (ii) PR-negative (0), and (iii) HER2-negative, defined by IHC (immunohistochemistry; IHC 0/1, non-overexpressing) or FISH (fluorescence in situ hybridization; FISH negative) or CISH (chromogen in situ hybridization; CISH negative).
- •Expression of LHRH receptor confirmed by IHC on archival (or current biopsy of breast tumor or metastatic site) breast cancer tissue
- •Progressive disease after failure of 1 to 3 prior chemotherapy regimens for recurrent or metastatic (Stage IV) disease (prior adjuvant/neoadjuvant therapy is allowed)
- •Measurable disease by RECIST 1.1 criteria; at least one target lesion that has not been previously irradiated.
排除标准
- •Eastern Cooperative Oncology Group (ECOG) performance status > 2
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or recent myocardial infarction (within 6 months of enrollment)
- •Leptomeningeal disease or brain metastases requiring steroids or other therapeutic intervention
- •Left ventricular ejection fraction (LVEF) < 50 %, determined by echocardiogram or MUGA scan
- •Compromised organ or marrow function as evidenced by any of the following:
- •thrombocyte count: < 100x109/L
- •absolute neutrophil count (ANC): < 1.5x109/L
- •hemoglobin: < 6.0 mmol/L (< 9 g/100 mL)
- •AS(A)T, AL(A)T: > 2.5 times upper limit of normal range (ULN) (> 5x ULN if clearly related to liver metastases)
- •bilirubin: > 1.5 mg/dL
- •creatinine: > 1.5 mg/dL or creatinine clearance < 40 mL/min.
- •Systemic anticancer therapy or radiotherapy within 21 calendar days of the first dose of study drug*)
- •* also excluded are patients with anticipated ongoing concomitant anticancer therapy during the study
- •Prior exposure to anthracyclines or anthracenediones for the treatment of metastatic breast cancer including liposomal doxorubicin (Doxil), doxorubicin, daunorubicin, or mitoxantrone
- •Prior adjuvant anthracyclines with a cumulative anthracycline dose ≥ 300 mg/m2
- •Ongoing therapeutic anticoagulation
- •Patients who are not surgically sterile or post-menopausal must agree to use for the duration of the study reliable methods of birth control defined as:
- •complete abstinence
- •any intrauterine device (IUD) with published data showing that the lowest expected failure rate is < 1 % per year, or
- •any other methods with published data showing that the lowest expected failure rate is less than 1 % per year
- •Investigational therapy within 30 calendar days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication).
研究组 & 干预措施
Arm A: AEZS-108
Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
干预措施: AEZS-108 (Drug)
Arm A: AEZS-108
Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
干预措施: Dexamethasone (Drug)
Arm B: Standard (SCCC)
commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;
- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).
干预措施: SCCC (Drug)
结局指标
主要结局
Efficacy of AEZS-108 compared to SSCC as measured by the median time of progression-free survival (PFS).
时间窗: Up to two years
PFS is defined as the time elapsed from randomization to the date of documented progression or death, whichever comes first. For surviving patients without progression who begin alternative treatment, PFS will be censored at the last date of documented progression-free status prior to starting alternative treatment. Similarly, losses to follow up will be censored at the last date of documented progression-free status.
次要结局
- Efficacy of AEZS-108: overall response(Up to two years)
- Efficacy of AEZS-108: clinical benefit(up to 2 years)
- Efficacy of AEZS-108: duration of response(up to 2 years)
- Efficacy of AEZS-108: time to progression (TTP)(up to 2 years)
- Efficacy of AEZS-108: overall survival(up to 2 years)
- Toxicity of AEZS-108 in this patient population(up to 2 years)